Abstract

Background

We previously reported a higher prevalence of nasal obstructive disorders (NOD) in pediatric patients with persistent allergic rhinitis (PER) not responding to medical treatment. The aim of this study was to determine the impact of NOD on quality of life (QoL) in this population.

Article

Photo published for Medical App Guides Treatment Decisions Using Patient Info

HELSINKI — A mobile app is being developed to make treatment recommendations to prescribers, using information provided by patients in a tandem system.

http://www.medscape.com/viewarticle/882357?src=rss

Hellings PW1, Akdis CA2, Bachert C3, Bousquet J4, Pugin B5, Adriaensen G6, Advani R7, Agache I8, Anjo C9, Anmolsingh R10, Annoni E11, Bieber T12, Bizaki A13, Braverman I14, Callebaut I1, Castillo Vizuete JA15, Chalermwatanachai T3, Chmielewski R16, Cingi C17, Cools L1, Coppije C5, Cornet ME6, De Boeck I18, De Corso E19, De Greve G1, Doulaptsi M20, Edmiston R7, Erskine S21, Gevaert E3, Gevaert P3, Golebski K22, Hopkins C23, Hox V24, Jaeggi C5, Joos G25, Khwaja S26, Kjeldsen A27, Klimek L28, Koennecke M29, Kortekaas Krohn I20, Krysko O3, Kumar BN30, Langdon C31, Lange B26, Lekakis G1, Levie P32, Lourijsen E6, Lund VJ33, Martens K20, Mösges R34, Mullol J35, Nyembue TD36, Palkonen S37, Philpott C21, Pimentel J38, Poirrier A39, Pratas AC21, Prokopakis E40, Pujols L35, Rombaux P41, Schmidt-Weber C42, Segboer C6, Spacova I43, Staikuniene J44, Steelant B20, Steinsvik EA45, Teufelberger A3, Van Gerven L1, Van Gool K46, Verbrugge R47, Verhaeghe B48, Virkkula P49, Vlaminck S50, Vries-Uss E47, Wagenmann M51, Zuberbier T52, Seys SF5, Fokkens WJ6.

Abstract

The first European Rhinology Research Forum organized by the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) was held in the Royal Academy of Medicine in Brussels on 17th and 18th November 2016, in collaboration with the European Rhinologic Society (ERS) and the Global Allergy and Asthma European Network (GA2LEN). One hundred and thirty participants (medical doctors from different specialties, researchers, as well as patients and industry representatives) from 27 countries took part in the multiple perspective discussions including brainstorming sessions on care pathways and research needs in rhinitis and rhinosinusitis. The debates started with an overview of the current state of the art, including weaknesses and strengths of the current practices, followed by the identification of essential research needs, thoroughly integrated in the context of Precision Medicine (PM), with personalized care, prediction of success of treatment, participation of the patient and prevention of disease as key principles for improving current clinical practices. This report provides a concise summary of the outcomes of the brainstorming sessions of the European Rhinology Research Forum 2016.

https://www.ncbi.nlm.nih.gov/pubmed/28501885

C. Cingi,corresponding author1 P. Gevaert,2 R. Mösges,3 C. Rondon,4 V. Hox,5 M. Rudenko,6 N. B. Muluk,7 G. Scadding,8 F. Manole,9 C. Hupin,10 W. J. Fokkens,11 C. Akdis,12 C. Bachert,2 P. Demoly,13 J. Mullol,14 A. Muraro,15 N. Papadopoulos,16 R. Pawankar,17 P. Rombaux,18 E. Toskala,19 L. Kalogjera,20 E. Prokopakis,21 P. W. Hellings,5 and J. Bousquet13

Abstract

This report has been prepared by the European Academy of Allergy and Clinical Immunology Task Force on Allergic Rhinitis (AR) comorbidities. The aim of this multidisciplinary European consensus document is to highlight the role of multimorbidities in the definition, classification, mechanisms, recommendations for diagnosis and treatment of AR, and to define the needs in this neglected area by a literature review. AR is a systemic allergic disease and is generally associated with numerous multi-morbid disorders, including asthma, eczema, food allergies, eosinophilic oesophagitis (EoE), conjunctivitis, chronic middle ear effusions, rhinosinusitis, adenoid hypertrophy, olfaction disorders, obstructive sleep apnea, disordered sleep and consequent behavioural and educational effects. This report provides up-to-date usable information to: (1) improve the knowledge and skills of allergists, so as to ultimately improve the overall quality of patient care; (2) to increase interest in this area; and (3) to present a unique contribution to the field of upper inflammatory disease.

Keywords: Adenoid hypertrophy, Allergic rhinitis (AR), Asthma, Chronic middle ear effusions, Comorbidities, Disordered sleep, Eczema, Eosinophilic oesophagitis (EoE), Conjunctivitis, Food allergies, Obstructive sleep apnea, Olfaction disorders, Rhinitis, Rhinosinusitis
Bousquet J1,2, Agache I3, Aliberti MR4, Angles R5, Annesi-Maesano I6, Anto JM7, Arnavielhe S8, Asayag E9, Bacci E10, Bedbrook A1, Bachert C11, Baroni I12, Barreto BA13, Bedolla-Barajas M14, Bergmann KC15, Bertorello L10, Bewick M16, Bieber T17, Birov S18, Bindslev-Jensen C19, Blua A20, Bochenska Marciniak M21, Bogus-Buczynska I21, Bosnic-Anticevich S22, Bosse I23, Bourret R24, Bucca C25, Buonaiuto R26, Caiazza D26, Caillot D27, Caimmi DP28, Camargos P29, Canfora G30, Cardona V31, Carriazo AM32, Cartier C33, Castellano G34, Chavannes NH35, Ciaravolo MM36, Cingi C37, Ciceran A38, Colas L39, Colgan E40, Coll J5, Conforti D41, de Sousa JC42, Cortés-Grimaldo RM14, Corti F43, Costa E44, Courbis AL45, Cousein E46, Cruz AA47, Custovic A48, Cvetkovski B22, Dario C49, da Silva M50, Dauvilliers Y51, De Blay F52, Dedeu T53, De Feo G54, De Martino B55, Demoly P28, De Vries G56, Di Capua Ercolano S57, Di Carluccio N58, Doulapsi M59, Dray G45, Dubakiene R60, Eller E19, Emuzyte R61, Espinoza-Contreras JM62, Estrada-Cardona A63, Farrell J40, Ferrero J64, Fokkens WJ65, Fonseca J66, Fontaine JF67, Forti S41, Gálvez-Romero JL68, García-Cobas CI14, Cruz MHG69, Gemicioğlu B70, van Wijk RG71, Guidacci M72, Gómez-Vera J73, Guldemond NA74, Gutter Z75, Haahtela T76, Hajjam J77, Hellings PW78, Hernández-Velázquez L79, Illario M80, Ivancevich JC81, Jares E82, Joos G83, Just J84, Kalayci O85, Kalyoncu AF86, Karjalainen J87, Keil T88, Khaltaev N89, Klimek L90, Kritikos V22, Kull I91, Kuna P21, Kvedariene V60, Kolek V92, Krzych-Fałta E93, Kupczyk M21, Lacwik P21, Larenas-Linnemann D94, Laune D8, Lauri D95, Lavrut J96, Lessa M97, Levato G98, Lewis L99, Lieten I100, Lipiec A93, Louis R101, Luna-Pech JA102, Magnan A39, Malva J103, Maspero JF104, Matta-Campos JJ105, Mayora O41, Medina-Ávalos MA106, Melén E107, Menditto E108, Millot-Keurinck J109, Moda G110, Morais-Almeida M111, Mösges R112, Mota-Pinto A113, Mullol J114, Muraro A115, Murray R116, Noguès M109, Nalin M12, Napoli L117, Neffen H118, O’Hehir RE22, Onorato G1, Palkonen S119, Papadopoulos NG120, Passalacqua G121, Pépin JL122, Pereira AM123, Persico M124, Pfaar O125, Pozzi AC126, Prokopakis E59, Raciborski F93, Rimmer J22, Rizzo JA127, Robalo-Cordeiro C128, Rodríguez-González M129, Rolla G110, Roller-Wirnsberger RE130, Romano A131, Romano M12, Salimäki J132, Samolinski B93, Serpa FS133, Shamai S112, Sierra M5, Sova M134, Sorlini M135, Stellato C54, Stelmach R136, Strandberg T137, Stroetmann V18, Stukas R138, Szylling A93, Tan R22, Tibaldi V110, Todo-Bom A139, Toppila-Salmi S76, Tomazic P140, Trama U141, Triggiani M54, Valero A142, Valovirta E143, Valiulis A144, van Eerd M56, Vasankari T145, Vatrella A54, Ventura MT146, Verissimo MT103, Viart F33, Williams S147, Wagenmann M148, Wanscher C149, Westman M150, Wickman M107, Young I151, Yorgancioglu A152, Zernotti E153, Zurbierber T15, Zurkuhlen A154, De Oliviera B155, Senn A155.

Abstract

The overarching goals of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) are to enable European citizens to lead healthy, active and independent lives while ageing. The EIP on AHA includes 74 Reference Sites. The aim of this study is to transfer innovation from an App developed by the MACVIA-France EIP on AHA reference site (Allergy Diary) to other reference sites. The phenotypic characteristics of rhinitis and asthma multimorbidity in adults and the elderly will be compared using validated information and communication technology (ICT) tools (i.e. the Allergy Diary and CARAT: Control of Allergic Rhinitis and Asthma Test) in 22 Reference Sites or regions across Europe. This will improve understanding, assessment of burden, diagnosis and management of rhinitis in the elderly by comparison with an adult population. Specific objectives will: (i) assess the percentage of adults and elderly who are able to use the Allergy Diary, (ii) study phenotypic characteristics and treatment over a period of one year of rhinitis and asthma multimorbidity at baseline (cross-sectional study) and (iii) follow-up using visual analogue scale (VAS). This part of the study may provide some insight into the differences between the elderly and adults in terms of response to treatment and practice. Finally (iv) work productivity will be examined in adults. This article is protected by copyright. All rights reserved.

KEYWORDS:

CARAT ; Allergy Diary; European Innovation Partnership on Active and Healthy Ageing; allergy; asthma; rhinitis

ΔΙΑΛΕΞΗ – ΠΑΡΟΥΣΙΑΣΗ

Τσακιροπούλου Ευαγγελία ΩΡΛ, MSc, PhD

Positin Paper